These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 4708057)

  • 1. DOPA and amino acid levels in plasma and cerebrospinal fluid of patients with Parkinson's disease before and during treatment with L-DOPA.
    Hare TA; Beasley BL; Chambers RA; Boehme DH; Vogel WH
    Clin Chim Acta; 1973 May; 45(3):273-80. PubMed ID: 4708057
    [No Abstract]   [Full Text] [Related]  

  • 2. Amino acid and dopa levels in plasma and urine from L-dopa-treated patients with Parkinson's disease.
    Hare TA; Vanna S; Beasley B; Chambers R; Vogel WH
    J Lab Clin Med; 1971 Feb; 77(2):319-25. PubMed ID: 5540775
    [No Abstract]   [Full Text] [Related]  

  • 3. [Disulfiram and L-dopa in patients with Parkinson's syndrome and in torsion dystonia].
    Serrano PA; Irigoyen M
    Prensa Med Mex; 1972; 37(7):246-50. PubMed ID: 4646433
    [No Abstract]   [Full Text] [Related]  

  • 4. 3-methoxy-4-hydroxyphenylalanine (3-O-methyldopa) in plasma during oral L-dopa therapy of patients with Parkinson's disease.
    Sharpless NS; Muenter MD; Tyce GM; Owen CA
    Clin Chim Acta; 1972 Mar; 37():359-69. PubMed ID: 5022100
    [No Abstract]   [Full Text] [Related]  

  • 5. CSF and plasma concentrations of free norepinephrine, dopamine, 3,4-dihydroxyphenylacetic acid (DOPAC), 3,4-dihydroxyphenylalanine (DOPA), and epinephrine in Parkinson's disease.
    Eldrup E; Mogensen P; Jacobsen J; Pakkenberg H; Christensen NJ
    Acta Neurol Scand; 1995 Aug; 92(2):116-21. PubMed ID: 7484057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of Parkinson's disease with L-DOPA and decarboxylase inhibitor.
    Rinne UK; Sonninen V; Sirtola T
    Z Neurol; 1972; 202(1):1-20. PubMed ID: 4114458
    [No Abstract]   [Full Text] [Related]  

  • 7. Effect of L-dopa on plasma free fatty acids and plasma glucose.
    Rivera-Calimlim L; Bianchine JR
    Metabolism; 1972 Jul; 21(7):611-7. PubMed ID: 5040916
    [No Abstract]   [Full Text] [Related]  

  • 8. An analysis of six patients with Parkinson's disease who have been unresponsive to L-dopa therapy.
    Mones RJ
    J Neurol Neurosurg Psychiatry; 1973 Jun; 36(3):362-7. PubMed ID: 4714098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. L-dopa therapy of Parkinson's disease: plasma L-dopa concentration, therapeutic response, and side effects.
    Muenter MD; Tyce GM
    Mayo Clin Proc; 1971 Apr; 46(4):231-9. PubMed ID: 5573818
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinical and cerebrospinal fluid changes in parkinsonian patients treated with L-3,4-dihydroxyphenylalanine (L-dopa).
    Sharpless NS; Ericsson AD; McCann DS
    Neurology; 1971 May; 21(5):540-9. PubMed ID: 5104098
    [No Abstract]   [Full Text] [Related]  

  • 11. Rapid estimation of DOPA in physiological fluids using the amino acid analyzer.
    Hare TA; Vogel WH
    Biochem Med; 1970 Nov; 4(3):277-81. PubMed ID: 5524069
    [No Abstract]   [Full Text] [Related]  

  • 12. Plasma 3-0-methyldopa in L-dopa therapy of Parkinson's disease.
    Muenter MD; Sharpless NS; Tyce GM
    Mayo Clin Proc; 1972 Jun; 47(6):389-95. PubMed ID: 5041685
    [No Abstract]   [Full Text] [Related]  

  • 13. L-dopa level in plasma, primary condition for the kinetic effect.
    Birkmayer W; Danielcyk W; Neumayer E; Riederer P
    J Neural Transm; 1973; 34(2):133-43. PubMed ID: 4722571
    [No Abstract]   [Full Text] [Related]  

  • 14. 3-O-Methyldopa, L-dopa, and trihexyphenidyl in the treatment of Parkinson's disease.
    Muenter MD; Dinapoli RP; Sharpless NS; Tyce GM
    Mayo Clin Proc; 1973 Mar; 48(3):173-83. PubMed ID: 4570387
    [No Abstract]   [Full Text] [Related]  

  • 15. Metabolism of levodopa in patients with Parkinson's disease. Radioactive and fluorometric assays.
    Morgan JP; Bianchine JR; Spiegel HE; Rivera-Calimlim L; Hersey RM
    Arch Neurol; 1971 Jul; 25(1):39-44. PubMed ID: 5146410
    [No Abstract]   [Full Text] [Related]  

  • 16. 'On-off' phenomenon in Parkinson's disease: relationship between dopa and other large neutral amino acids in plasma.
    Eriksson T; Granérus AK; Linde A; Carlsson A
    Neurology; 1988 Aug; 38(8):1245-8. PubMed ID: 3135513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dihydroxyphenylalanine (DOPA) in plasma during dopa treatment of patients with Parkinson's disease.
    Tyce GM; Muenter MD; Owen CA
    Mayo Clin Proc; 1970 Jun; 45(6):438-43. PubMed ID: 5425103
    [No Abstract]   [Full Text] [Related]  

  • 18. [Biochemical aspects of the effect of L-dopa in patients with Parkinson's disease].
    Gründig E; Gerstenbrand F; Oberhummer J; Simanyi M; Schedl R; Weiss J
    Z Neurol; 1972; 203(1):73-90. PubMed ID: 4118094
    [No Abstract]   [Full Text] [Related]  

  • 19. Cerebrospinal fluid amino acids in extrapyramidal disorders before and after L-DOPA treatment.
    Van Sande M; Caers J; Lowenthal A
    Z Neurol; 1971 Apr; 199(1):24-9. PubMed ID: 4102746
    [No Abstract]   [Full Text] [Related]  

  • 20. [Effect of L-dopa on pituitary TSH and GH secretion in Parkinson's disease].
    Sakoda M; Kusaka T; Baba S; Shirakata S
    Nihon Naibunpi Gakkai Zasshi; 1972 Jul; 48(4):241-4. PubMed ID: 5066290
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.